NCT07419932 Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
| NCT ID | NCT07419932 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fujian Medical University |
| Condition | Thyroid Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-12-23 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 14 years at enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). * LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board. * For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team. * Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Normal function of major organs. * Written informed consent obtained. Exclusion Criteria: * Patients who refuse tumor tissue biopsy or surgery. * Prior thyroid or major neck surgery. * History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan. * Concurrent active malignancies. * Uncontrolled systemic diseases, including diabetes, hypertension, etc. * Pregnancy or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07419932 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 80 Years, studying Thyroid Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07419932 currently recruiting?
Yes, NCT07419932 is actively recruiting participants. Contact the research team at fzhzwx6688@163.com for enrollment information.
Where is the NCT07419932 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07419932 clinical trial?
NCT07419932 is sponsored by Fujian Medical University. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.